Maternal exposure to the synthetic cannabinoid HU-210: Effects on the endocrine and immune systems of the adult male offspring

NeuroImmunoModulation

Volumn 7, Issue 1, 2000, Pages 16-26

  Del Arco, Ignacio ^a   Muñoz, Raúl ^a   Rodríguez De Fonseca, Fernando ^a   Escudero, Leticia ^a   Martín Calderón, Jose Luis ^a   Navarro, Miguel ^a   Villanúa, Maria Angeles ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoids; Corticosterone; HU 210; Immunity; Lymphocyte subpopulations; Perinatal exposure; Rat

Indexed keywords

CANNABINOID RECEPTOR; CONCANAVALIN A; CORTICOSTEROID; DEXANABINOL; FOLLITROPIN; GROWTH HORMONE; LIPOPOLYSACCHARIDE; LUTEINIZING HORMONE; PROLACTIN; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; LACTATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; SPLEEN LYMPHOCYTE;

EID: 1642588142     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026416     Document Type: Article

References (48)

1. Dewey WL: Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-178.
2. Robins LN, Mills JL: Effects of in utero exposure to street drugs. Am J Publ Health 1993; 83(suppl):8-32.
3. Zuckerman B: Drug effects - A search for mechanisms; in Kilbey MN, Asghar K (eds): Methodological Issues on Controlled Studies on Effects of Prenatal Exposure to Drug Abuse. NIDA Research Mongraph 1991, Vol 114, pp 352-362.
4. Dalterio S, Bartke A: Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 1979;205:1420-1422.
5. Fride E, Mechoulam R: Developmental aspects of anandamide: Ontogeny of response and prenatal exposure. Psychoneuroendocrinology 1996;21:157-172.
6. Navarro M, Rodríguez de Fonseca F, Hernández ML, Ramos JA, Fernández-Ruiz JJ: Changes in the adult motor behavior following perinatal cannabinoid exposure in rats: Involvement of nigrostriatal dopaminergic activity. Pharmacol Biochem Behav 1994;47:47-58.
7. Navarro M, de Miguel R, Rodríguez de Fonseca F, Ramos JA, Fernández-Ruiz JJ: Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behav Brain Res 1996;75:91-98.
8. Rodríguez de Fonseca F, Cebeira M, Fernández-Ruiz JJ, Navarro M, Ramos JA: Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience 1991;43:713-723.
9. 9-tetrahydrocannabinol in rats: Possible role of pituitary-adrenal axis. Life Sci 1995;56:2169-2176.
10. Walters DE, Carr LA: Changes in brain catecholamine mechanisms following perinatal exposure to marihuana. Pharmacol Biochem Behav 1986;25:763-778.
11. 9-tetrahydrocannabinol in mice. Dev Brain Res 1996;95:131-134.
12. Murphy LL, Gher J, Szary A: Effects of prenatal exposure to delta-9-tetrahydrocannabinol on reproductive, endocrine and immune parameters of the male and the female rat offspring. Endocrine 1995;3:875-881.
13. Wenger T, Croix D, Tramu G, Leonardelli J: Prenatally administered delta-9-tetrahydrocannabinol temporarily inhibits the developing hypothalamo-pituitary system in rats. Pharmacol Biochem Behav 1991;40:599-602.
14. Wenger T, Fragkakis P, Giannikou P, Yiannakakis N: The effects of prenatally administered endogenous cannabinoid on rat offspring. Pharmacol Biochem Behav 1997;58:537-544.
15. Felder CC, Joyce KE, Biley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48:443-450.
16. Herkenham M, Lynn AB, Little MD, Johnson MR, McIvin LS, De Costa BR, Rice KC: Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA 1990;87:1932-1936.
17. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1994;346:561-563.
18. Rodríguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F: Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276:2050-2054.
19. Rodríguez de Fonseca FA, Fernández-Ruiz JJ, Eldridge JC, Steger RW, Bartke A, Murphy LL: Effects of the exposure to delta-9-tetrahydrocannabinol on the adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol Biochem Behav 1991;40:593-598.
20. Rodrígucz de Fonseca F, Villanúa MA, Muñoz RM, San-Martin-Clarke O, Navarro M: Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology 1995;61:714-721.
21. Weidenfeld J, Feldman S, Mechoulam R: Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamus-pituitary-adrenal axis in the rat. Neuroendocrinology 1992;59:110-114.
22. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocytes subpopulations. Eur J Biochem 1995;232:54-61.
23. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR: Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. J Pharmacol Exp Ther 1992;42:736-742.
24. Pross SH, Klein TW, Newton CA, Smith J, Widen R, Friedman H: Differential suppression of T-cell subpopulations by THC [delta-9-tetrahydrocannabinol]. Int J Immunopharmacol 1989;12:539-544.
25. Daaka Y, Klein TW, Friedman H: Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 1996;276:776-783.
26. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to the cannabinoid receptor. Biochem Pharmacol 1995; 50:83-90.
27. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, Ploemacher R, Mayen A, Lowemberg B, Dehwel R: Anandamide, a natural ligand for the peripheral cannabinoid receptor, is a novel synergistic growth factor for hematopoietic cells. Blood 1997;90:1448-1457.
28. Deroq JM, Segui M, Marchand J, Lefur G, Casellas P: Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 1995;369:177-182.
29. 9-tetrahydrocannabinol. Life Sci 1997;60:1709-1717.
30. Nahas GG, Suciu-Foca N, Armand JP: Inhibition of cellular immunity in marijuana smokers. Science 1974;183:419-421.
31. 14C-tetrahydrocannabinol to the mother. Eur J Pharmacol 1977;22:221-223.
32. Rodríguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ: Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 1993;4:135-138.
33. Mirmiran M, Swaab DF: Influence of drugs on brain neurotransmission and behavioral stages during development. Dev Pharmacol Ther 1987;10:377-384.
34. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, Cornelius MD: Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol 1994;16:169-175.
35. Kumar AM, Hancy M, Becker T, Thompson ML, Kream RM, Miczek K: Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotrophin-releasing hormone and substance P in the adult male rat brain. Brain Res 1990;525:78-83.
36. McCormick CM, Smythe JW, Sharma S, Meaney M: Sex-specific effects of prenatal stress on hypothalamic-pituitary-adrenal responses to stress and brain glucocorticoid receptor density in adult rats. Brain Res 1995;84:55-61.
37. McEwen BS: Steroid hormones and brain development: Some guidelines for understanding actions of pseudohormones and other toxic agents. Environ Health Pers 1987;74:177-192.
38. 9-tetrahydro-cannabinol toxicity in rats treated for periods up to six months. Toxicol Appl Pharmacol 1975;32: 399-417.
39. Navarro M, Rubio P, Rodríguez de Fonseca F: Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology 1995;122:1-14.
40. 9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Bchav 1998;61:229-238.
41. 37)CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996;276:56-64.
42. Janossy G, Greaves MJ, Dohendoff MJ, Snajder J: Lymphocyte activation V. Quantitation of the proliferative responses to mitogens using defined T and B populations. Clin Exp Immunol 1973;14:581-589.
43. Mossman T: Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-62.
44. Hutchings DE, Morgan B, Brake SC, Shi T, Lasalle E: Delta-9-tetrahydrocannabinol during pregnancy in the rat: I. Differential effects on maternal nutrition, embryotoxicity and growth in the offspring. Neurotoxicol Teratol 1987;9:39-44.
45. Brake SC, Hutchings DE, Morgan B, Lasalle E, Shi T: Delta-9-tetrahydrocannabinol during pregnancy in the rat: II. Effects on ontogeny of locomotor activity and nipple attachment in the offspring. Neurotoxicol Teratol 1987;9:45-49.
46. 8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998;344:77-86.
47. Taylor AN, Branch BJ, Nelson LR, Fane LA, Poland RE: Prenatal ethanol and ontogeny of pituitary-adrenal responses to ethanol and morphine. Alcohol 1986;3:255-259.
48. Ward IL, Weisz J: Differential effects of maternal stress on circulating levels of corticosterone, progesterone and testosterone in male and female rat fetuses and their mothers. Endocrinology 1984;114:1635-1644.